Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

December 14th 2023Access Considerations for Gene Therapies Among Patients With Rare Diseases ...

Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] Technology appraisal guidance TBC ERC1671 for treating progressed or recurrent grade IV ...

With a portfolio of marketed products, including EPKINLY, TEPKINLY, and Tivdak, and a robust pipeline featuring Epcoritamab and tisotumab vedotin, it’s advancing groundbreaking treatments in ...

Highlights from Woyach, professor in the division of hematology at The Ohio State University, include a study that evaluated epcoritamab (Epkinly; Genmab, AbbVie) monotherapy, and another that ...

Bispecific antibodies offer outpatient treatment options, increasing access to advanced therapies in community settings and reducing the burden of travel for patients. Recent approvals and ...

Results from the Phase Ib/II EPCORE NHL-2 trial demonstrate that the combination of epcoritamab, a CD3xCD20 bispecific antibody, and GemOx (gemcitabine plus oxaliplatin) offers deep and durable ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline ...

Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed/refractory DLBCL. The regimen also significantly extended survival. The addition of ...

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non ...